Clinical Trial

Aetion Announces Leadership Changes

Kevin Riley, industry leader with global experience in technology commercialization, joins as presidentCarolyn Magill steps down as CEO; Jeremy Rassen,…

4 months ago

ESMO 2024: Stay Informed with Real-Time Coverage and Analysis from DelveInsight

As the stage is set for another year of groundbreaking research and transformative treatment advancements, several companies are seizing the…

4 months ago

MIE2024 Conference article shows material data quality improvement and time savings in clinical trial data capture with nCartes

FREMONT, Calif., Sept. 12, 2024 /PRNewswire/ -- The 34th Medical Informatics Europe Conference was held in Athens, Greece August 25-29, 2024.…

4 months ago

PhaseV Unveils Machine Learning-Powered Platform to Improve Oncology Clinical Trials

Company Leverages Causal Machine Learning to Overcome Key Challenges in Developing New Cancer Treatments BOSTON, Sept. 12, 2024 /PRNewswire/ --…

4 months ago

SOPHiA GENETICS Announces Poster Presentations at ESMO 2024

Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and…

4 months ago

Sema Slim: A New Safe and Effective Medical Weight Loss Solution Now Available Online

MIAMI, FL / ACCESSWIRE / September 12, 2024 / Sema Slim™, the premier online destination for effective telehealth services in…

4 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all…

4 months ago

Yunu Extends Free Cancer Center Use of Platform for All Children’s Oncology Group Clinical Trials

CARY, NC / ACCESSWIRE / September 12, 2024 / Yunu, a leading provider of clinical trial imaging workflow and data…

4 months ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed…

4 months ago